<p>Oppenheimer  Co. Inc. 在最近向证券交易委员会提交的 13F 表格中表示，在第四季度将其在 Hims  Hers Health, Inc. (NYSE:HIMS - 免费报告) 的持仓减少了 83.8%。该机构投资者在此期间出售了 37,448 股后，持有该公司 7,254 股股票。Oppenheimer  Co. Inc. 在 Hims  Hers Health 的持股在最近一个季度末价值 236,000 美元。</p>
<p>获取 <strong>Hims  Hers Health</strong> 警报：</p>
<ul>
<li>Hims  Hers 财报前瞻：诺和诺德的转变将 GLP-1 策略置于焦点</li>
</ul>
<p>其他对冲基金最近也对该公司的持仓进行了调整。Pathway Capital Management LP 在第三季度购买了 Hims  Hers Health 的新股份，价值约 6,766,000 美元。Steadview Capital Management LLC 在第三季度将其在 Hims  Hers Health 的持仓提高了 80.0%。Steadview Capital Management LLC 目前持有该公司 701,845 股股票，价值 39,809,000 美元，此前在上个季度又购买了 311,845 股。Farallon Capital Management LLC 在第三季度将其在 Hims  Hers Health 的持仓提高了 30.8%。Farallon Capital Management LLC 目前持有该公司 10,746,852 股股票，价值 609,561,000 美元，此前在上个季度又购买了 2,533,271 股。BIT Capital GmbH 在第三季度将其在 Hims  Hers Health 的持仓提高了 73.8%。BIT Capital GmbH 目前持有该公司 2,210,384 股股票，价值 125,373,000 美元，此前在上个季度又购买了 938,728 股。最后，密歇根州退休系统在第三季度将其在 Hims  Hers Health 的持仓提高了 49.2%。密歇根州退休系统目前持有该公司 2,057,700 股股票，价值 116,713,000 美元，此前在上个季度又购买了 678,600 股。63.52% 的股票目前由对冲基金和其他机构投资者持有。</p>
<h2>Hims  Hers Health 股票上涨 0.7%</h2>
<p>NYSE:HIMS 的股票周一开盘价为 28.46 美元。该公司的流动比率为 1.90，速动比率为 1.70，债务与股本比率为 1.80。Hims  Hers Health, Inc. 的 12 个月最低价为 13.74 美元，最高价为 70.43 美元。该公司的 50 日移动平均价格为 22.56 美元，200 日移动平均价格为 29.75 美元。该公司的市值为 64.9 亿美元，市盈率为 55.81，PEG 比率为 3.85，贝塔值为 2.43。</p>
<ul>
<li>FDA 最新提案对 Lilly、Novo 和 Hims 的影响</li>
</ul>
<p>Hims  Hers Health (NYSE:HIMS - 获取免费报告) 最近于 2 月 23 日星期一公布了季度财报。该公司报告本季度每股收益为 0.08 美元，超出分析师共识预期的 0.02 美元，超出幅度为 0.06 美元。Hims  Hers Health 的净利润率为 5.47%，股本回报率为 22.48%。该公司本季度的收入为 6.1782 亿美元，而共识预期为 6.1948 亿美元。去年同期，该公司每股收益为 0.11 美元。该公司本季度的收入较去年同期增长了 28.4%。整体来看，股票研究分析师预测 Hims  Hers Health, Inc. 本年度每股收益将达到 0.53 美元。</p>
<h2>华尔街分析师观点</h2>
<p>HIMS 一直是多份研究分析师报告的主题。Leerink Partners 在 3 月 16 日的研究报告中将 Hims  Hers Health 的目标价从 17.50 美元上调至 25.00 美元，并给予该股票 &#34;市场表现&#34; 的评级。Needham  Company LLC 在 3 月 9 日的报告中将 Hims  Hers Health 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;，并设定了 30.00 美元的目标价。TD Cowen 在 3 月 27 日的报告中将 Hims  Hers Health 的目标价从 25.00 美元下调至 23.00 美元，并对该公司给予了 &#34;持有&#34; 的评级。Truist Financial 在 2 月 24 日的报告中重申了 &#34;持有&#34; 的评级，并对 Hims  Hers Health 的股票设定了 18.00 美元的目标价（低于 37.00 美元）。最后，巴克莱在 3 月 11 日的报告中将 Hims  Hers Health 的目标价从 25.00 美元上调至 29.00 美元，并给予该公司 &#34;超配&#34; 的评级。四位分析师对该股票给予了买入评级，十二位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，Hims  Hers Health 目前的共识评级为 &#34;持有&#34;，平均目标价为 31.86 美元。</p>
<ul>
<li>亚马逊对 Hims 的影响：其 GLP-1 进入意味着什么</li>
</ul>
<p><strong>获取我们最新的 HIMS 股票报告</strong></p>
<h2>内部活动</h2>
<p>在其他 Hims  Hers Health 的新闻中，内部人士 Irene Becklund 于 3 月 17 日星期二出售了 5,529 股该公司的股票。股票以平均价格 24.69 美元出售，总价值为 136,511.01 美元。出售完成后，内部人士持有该公司 8,752 股股票，价值 216,086.88 美元。此交易代表其持股减少了 38.72%。该出售在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，内部人士 Soleil Boughton 于 4 月 20 日星期一出售了 9,463 股该公司的股票。股票以平均价格 30.00 美元出售，总交易额为 283,890.00 美元。出售完成后，内部人士直接持有该公司 299,368 股股票，价值约 8,981,040 美元。该交易的持仓减少了 3.06%。有关此出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在过去九十天内出售了价值 5,285,706 美元的 204,857 股公司股票。11.76% 的股票目前由公司内部人士持有。</p>
<h2>Hims  Hers Health 概况</h2>
<p>(免费报告)</p>
<p>Hims &amp; Hers Health, Inc 是一个远程医疗平台，在美国提供直接面向消费者的个人护理产品和虚拟医疗服务。该公司以 Hims &amp; Hers 品牌运营，提供一个综合的数字体验，将用户与持牌医疗提供者连接起来，使其能够进行在线咨询和开处方，涵盖多种健康状况。其远程医疗基础设施支持处方药和非处方产品，并提供送货上门服务。</p>
<p>公司的产品组合涵盖男性和女性健康的关键领域，包括脱发治疗、性健康疗法、护肤方案和心理健康支持。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票超过 Hims &amp; Hers Health</li>
<li>超越 NVIDIA：强劲势头的 Picks-and-Shovels AI 投资</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后看到提振，FanDuel 显示复苏迹象</li>
<li>3 只医疗股票将从这项重大法案中受益</li>
</ul>
<p><strong>想看看其他对 HIMS 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Hims &amp; Hers Health, Inc. (NYSE:HIMS - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Hims &amp; Hers Health 吗？</h2>
<p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Hims &amp; Hers Health 并不在名单上。</p>
<p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HIMS

2 倍做多 HIMS ETF - Defiance

HIMY

<p>Oppenheimer & Co. Inc. 已显著减少在 Hims & Hers Health, Inc. 的持股，减少幅度达到 83.8%，目前持有 7,254 股，此前在第四季度出售了 37,448 股。其他对冲基金也调整了他们的持仓，其中 Pathway Capital Management 和 Steadview Capital Management 的增持尤为显著。Hims & Hers Health 的股票开盘价为 28.46 美元，市值为 64.9 亿美元，最近的每股收益为 0.08 美元，超出预期。分析师的评级意见不一，目标价格范围在 18.00 美元到 30.00 美元之间</p>

<p>Oppenheimer &amp; Co. Inc. reduced its position in Hims &amp; Hers Health, Inc. (NYSE:HIMS - Free Report) by 83.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,254 shares of the company's stock after selling 37,448 shares during the period. Oppenheimer &amp; Co. Inc.'s holdings in Hims &amp; Hers Health were worth $236,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Oppenheimer  Co. Inc. 在最近向证券交易委员会提交的 13F 表格中表示，在第四季度将其在 Hims  Hers Health, Inc. (NYSE:HIMS - 免费报告) 的持仓减少了 83.8%。该机构投资者在此期间出售了 37,448 股后，持有该公司 7,254 股股票。Oppenheimer  Co. Inc. 在 Hims  Hers Health 的持股在最近一个季度末价值 236,000 美元。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims  Hers Health</strong> 警报：</p>
</div><ul>
<li>Hims &amp; Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims  Hers 财报前瞻：诺和诺德的转变将 GLP-1 策略置于焦点</li>
</ul>
</div><p>Other hedge funds also recently made changes to their positions in the company. Pathway Capital Management LP purchased a new stake in shares of Hims &amp; Hers Health in the third quarter worth about $6,766,000. Steadview Capital Management LLC lifted its position in shares of Hims &amp; Hers Health by 80.0% in the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company's stock worth $39,809,000 after buying an additional 311,845 shares in the last quarter. Farallon Capital Management LLC lifted its position in shares of Hims &amp; Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock worth $609,561,000 after buying an additional 2,533,271 shares in the last quarter. BIT Capital GmbH lifted its position in shares of Hims &amp; Hers Health by 73.8% in the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company's stock worth $125,373,000 after buying an additional 938,728 shares in the last quarter. Finally, State of Michigan Retirement System lifted its position in shares of Hims &amp; Hers Health by 49.2% in the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company's stock worth $116,713,000 after buying an additional 678,600 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他对冲基金最近也对该公司的持仓进行了调整。Pathway Capital Management LP 在第三季度购买了 Hims  Hers Health 的新股份，价值约 6,766,000 美元。Steadview Capital Management LLC 在第三季度将其在 Hims  Hers Health 的持仓提高了 80.0%。Steadview Capital Management LLC 目前持有该公司 701,845 股股票，价值 39,809,000 美元，此前在上个季度又购买了 311,845 股。Farallon Capital Management LLC 在第三季度将其在 Hims  Hers Health 的持仓提高了 30.8%。Farallon Capital Management LLC 目前持有该公司 10,746,852 股股票，价值 609,561,000 美元，此前在上个季度又购买了 2,533,271 股。BIT Capital GmbH 在第三季度将其在 Hims  Hers Health 的持仓提高了 73.8%。BIT Capital GmbH 目前持有该公司 2,210,384 股股票，价值 125,373,000 美元，此前在上个季度又购买了 938,728 股。最后，密歇根州退休系统在第三季度将其在 Hims  Hers Health 的持仓提高了 49.2%。密歇根州退休系统目前持有该公司 2,057,700 股股票，价值 116,713,000 美元，此前在上个季度又购买了 678,600 股。63.52% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><h2>Hims &amp; Hers Health Stock Up 0.7%</h2>
<div class="lb-trans"><h2>Hims  Hers Health 股票上涨 0.7%</h2>
</div><p>Shares of NYSE:HIMS opened at $28.46 on Monday. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. Hims &amp; Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43. The company has a 50-day moving average price of $22.56 and a 200 day moving average price of $29.75. The company has a market cap of $6.49 billion, a price-to-earnings ratio of 55.81, a PEG ratio of 3.85 and a beta of 2.43.</p>
<div class="lb-trans"><p>NYSE:HIMS 的股票周一开盘价为 28.46 美元。该公司的流动比率为 1.90，速动比率为 1.70，债务与股本比率为 1.80。Hims  Hers Health, Inc. 的 12 个月最低价为 13.74 美元，最高价为 70.43 美元。该公司的 50 日移动平均价格为 22.56 美元，200 日移动平均价格为 29.75 美元。该公司的市值为 64.9 亿美元，市盈率为 55.81，PEG 比率为 3.85，贝塔值为 2.43。</p>
</div><ul>
<li>What the FDA's Latest Proposal Means for Lilly, Novo, and Hims</li>
</ul>
<div class="lb-trans"><ul>
<li>FDA 最新提案对 Lilly、Novo 和 Hims 的影响</li>
</ul>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.06. Hims &amp; Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The firm had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same quarter last year, the firm earned $0.11 EPS. The firm's revenue for the quarter was up 28.4% compared to the same quarter last year. As a group, equities research analysts predict that Hims &amp; Hers Health, Inc. will post 0.53 earnings per share for the current year.</p>
<div class="lb-trans"><p>Hims  Hers Health (NYSE:HIMS - 获取免费报告) 最近于 2 月 23 日星期一公布了季度财报。该公司报告本季度每股收益为 0.08 美元，超出分析师共识预期的 0.02 美元，超出幅度为 0.06 美元。Hims  Hers Health 的净利润率为 5.47%，股本回报率为 22.48%。该公司本季度的收入为 6.1782 亿美元，而共识预期为 6.1948 亿美元。去年同期，该公司每股收益为 0.11 美元。该公司本季度的收入较去年同期增长了 28.4%。整体来看，股票研究分析师预测 Hims  Hers Health, Inc. 本年度每股收益将达到 0.53 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>HIMS has been the topic of a number of research analyst reports. Leerink Partners boosted their target price on Hims &amp; Hers Health from $17.50 to $25.00 and gave the stock a &#34;market perform&#34; rating in a research report on Monday, March 16th. Needham &amp; Company LLC raised shares of Hims &amp; Hers Health from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $30.00 price target for the company in a report on Monday, March 9th. TD Cowen lowered their price target on shares of Hims &amp; Hers Health from $25.00 to $23.00 and set a &#34;hold&#34; rating for the company in a report on Friday, March 27th. Truist Financial reaffirmed a &#34;hold&#34; rating and issued a $18.00 price target (down from $37.00) on shares of Hims &amp; Hers Health in a report on Tuesday, February 24th. Finally, Barclays increased their price target on shares of Hims &amp; Hers Health from $25.00 to $29.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, March 11th. Four analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Hims &amp; Hers Health currently has a consensus rating of &#34;Hold&#34; and an average target price of $31.86.</p>
<div class="lb-trans"><p>HIMS 一直是多份研究分析师报告的主题。Leerink Partners 在 3 月 16 日的研究报告中将 Hims  Hers Health 的目标价从 17.50 美元上调至 25.00 美元，并给予该股票 &#34;市场表现&#34; 的评级。Needham  Company LLC 在 3 月 9 日的报告中将 Hims  Hers Health 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;，并设定了 30.00 美元的目标价。TD Cowen 在 3 月 27 日的报告中将 Hims  Hers Health 的目标价从 25.00 美元下调至 23.00 美元，并对该公司给予了 &#34;持有&#34; 的评级。Truist Financial 在 2 月 24 日的报告中重申了 &#34;持有&#34; 的评级，并对 Hims  Hers Health 的股票设定了 18.00 美元的目标价（低于 37.00 美元）。最后，巴克莱在 3 月 11 日的报告中将 Hims  Hers Health 的目标价从 25.00 美元上调至 29.00 美元，并给予该公司 &#34;超配&#34; 的评级。四位分析师对该股票给予了买入评级，十二位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，Hims  Hers Health 目前的共识评级为 &#34;持有&#34;，平均目标价为 31.86 美元。</p>
</div><ul>
<li>Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means</li>
</ul>
<div class="lb-trans"><ul>
<li>亚马逊对 Hims 的影响：其 GLP-1 进入意味着什么</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on HIMS</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 HIMS 股票报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other Hims &amp; Hers Health news, insider Irene Becklund sold 5,529 shares of the firm's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the sale, the insider owned 8,752 shares of the company's stock, valued at $216,086.88. This trade represents a 38.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, insider Soleil Boughton sold 9,463 shares of the firm's stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $30.00, for a total transaction of $283,890.00. Following the completion of the sale, the insider directly owned 299,368 shares of the company's stock, valued at approximately $8,981,040. The trade was a 3.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 204,857 shares of company stock worth $5,285,706 in the last ninety days. 11.76% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Hims  Hers Health 的新闻中，内部人士 Irene Becklund 于 3 月 17 日星期二出售了 5,529 股该公司的股票。股票以平均价格 24.69 美元出售，总价值为 136,511.01 美元。出售完成后，内部人士持有该公司 8,752 股股票，价值 216,086.88 美元。此交易代表其持股减少了 38.72%。该出售在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，内部人士 Soleil Boughton 于 4 月 20 日星期一出售了 9,463 股该公司的股票。股票以平均价格 30.00 美元出售，总交易额为 283,890.00 美元。出售完成后，内部人士直接持有该公司 299,368 股股票，价值约 8,981,040 美元。该交易的持仓减少了 3.06%。有关此出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在过去九十天内出售了价值 5,285,706 美元的 204,857 股公司股票。11.76% 的股票目前由公司内部人士持有。</p>
</div><h2>Hims &amp; Hers Health Profile</h2>
<div class="lb-trans"><h2>Hims  Hers Health 概况</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Hims &amp; Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims &amp; Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc 是一个远程医疗平台，在美国提供直接面向消费者的个人护理产品和虚拟医疗服务。该公司以 Hims &amp; Hers 品牌运营，提供一个综合的数字体验，将用户与持牌医疗提供者连接起来，使其能够进行在线咨询和开处方，涵盖多种健康状况。其远程医疗基础设施支持处方药和非处方产品，并提供送货上门服务。</p>
</div><p>The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.</p>
<div class="lb-trans"><p>公司的产品组合涵盖男性和女性健康的关键领域，包括脱发治疗、性健康疗法、护肤方案和心理健康支持。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Hims &amp; Hers Health</li>
<li>超越 NVIDIA：强劲势头的 Picks-and-Shovels AI 投资</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后看到提振，FanDuel 显示复苏迹象</li>
<li>3 只医疗股票将从这项重大法案中受益</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding HIMS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims &amp; Hers Health, Inc. (NYSE:HIMS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 HIMS 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Hims &amp; Hers Health, Inc. (NYSE:HIMS - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Hims &amp; Hers Health 吗？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Hims &amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Oppenheimer & Co. Inc. Cuts Holdings in Hims & Hers Health, Inc. $HIMS

Market Beat

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

奥本海默控股

诺和诺德公司

礼来

Truist Financial

巴克莱银行

亚马逊

Oppenheimer & Co. Inc. 减持了 Hims & Hers Health, Inc. 的持股 $HIMS